Neurocrine Biosciences Inc at Cowen Health Care Conference (Virtual) Transcript
Good morning, and welcome once again to Cowen & Company's 42nd Annual Healthcare Conference. I'm Phil Nadeau, I'm a biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with CEO of Neurocrine, Kevin Gorman. Those of you who follow our research know that we are fans of Neurocrine as we think there is much growth left in INGREZZA and an undiscovered pipeline.
Kevin, maybe I'll hand it to you to give a brief state of the company overview, biggest trends, biggest challenges and what you think needs to happen for Neurocrine to drive outperformance over the next couple of years.
Thanks, Phil. Good to see you. I'm here in a hotel room in your [fair] city of Boston. So bear with me, I'm trying to make sure that at least the audio is going to stay very stable in here, the video may click around a little bit. So kind of working off of 2 devices here. And I will start out with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |